Table 3.
Baseline Characteristics of the Add-On Study
| Placebo (n = 8) | IONIS-AGT-LRx (n = 18) | |
|---|---|---|
| Age (yrs) | 61 ± 10 | 60 ± 8 |
| Male | 2 (25) | 4 (22) |
| Female | 6 (75) | 14 (78) |
| White | 4 (50) | 15 (83) |
| BMI (kg/m2) | 29.4 ± 4.2 | 28.1 ± 4.6 |
| Hyperlipidemia | 4 (50) | 13 (72) |
| Type 2 diabetes mellitus | 3 (38) | 5 (28) |
| AGT (μg/ml) baseline | 25.5 ± 4.4 | 25.1 ± 3.3 |
| SBP (mm Hg) | 152 ± 8 | 154 ± 11 |
| DBP (mm Hg) | 87 ± 8 | 89 ± 9 |
| Baseline diuretic used | 6 (75) | 11 (61) |
| Number of anti hypertensive meds | ||
| 2 | 6 (75) | 11 (61) |
| 3 | 2 (25) | 7 (39) |
| High-dose ACEi/ARB∗ | 3 (38) | 7 (39) |
| Creatinine (mg/dl) | 0.87 ± 0.11 | 0.77 ± 0.19 |
| eGFR (ml/min/1.73 m2) | 84 ± 15 | 89 ± 13 |
| Potassium (mmol/l) | 4.3 ± 0.5 | 4.2 ± 0.4 |
| Angiotensin II (ng/l) | 19 ± 6 | 32 ± 35 |
| Aldosterone (ng/dl) | 13.6 ± 4.5 | 9.7 ± 5.1 |
| Renin mass (pg/ml) | 8.2 ± 6.1 | 36.2 ± 72.7 |
| Plasma renin activity (ng/ml/h) | 1.0 ± 1.0 | 3.9 ± 5.8 |
Values are mean ± SD or n (%).
Abbreviations as in Table 1.
∗
High-dose ACEi/ARB was defined based on the average approved doses per package insert.